



1646  
PATENT  
Customer No. 22,852  
Attorney Docket No. 4853.0085

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
)  
OGATA et al. ) Group Art Unit: 1646  
)  
Application No.: 10/019,501 ) Examiner: Not Yet Assigned  
)  
PCT Filing Date: July 3, 2000 )  
)  
§ 371 Date: December 31, 2001 )  
)  
For: AGENT FOR AMELIORATING )  
LOW VASOPRESSIN LEVEL )

Commissioner for Patents  
Washington, DC 20231

Sir:

RECEIVED  
OCT 15 2002  
TECH CENTER 1600/2900

**TRANSMITTAL LETTER**

Prior to the examination of the above application, the following items checked below are appropriate:

The claims are calculated below:

	Claims Remaining After Amendment		Highest Number Previously Paid	Present Extra	Rate	Additional Fee
Total	28	-	19	9	x \$ 18	\$ 162.00
Indep.	5	-	4	1	x \$ 84	84.00
<input type="checkbox"/> First Presentation of Multiple Dep. Claim(s)					+\$280	
Subtotal						\$ 246.00
Reduction by ½ if small entity						-
TOTAL						\$ 246.00

■ A fee of \$ 246.00 to cover the cost of the additional claims is enclosed.

Please grant any extensions of time required to enter this response and charge any additional required fees to our deposit account 06-0916.

Dated: October 9, 2002

By: Rebecca M. McNeill  
Rebecca M. McNeill  
Reg. No. 43,796

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



6/3

PATENT  
Customer No. 22,852  
Attorney Docket No. 4853.0085-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: )  
OGATA et al. ) Group Art Unit: 1646  
Application No.: 10/019,501 ) Examiner: Not yet assigned  
PCT Filing Date: July 3, 2000 )  
§371 Date: December 31, 2001 )  
For: AGENT FOR AMELIORATING )  
LOW VASOPRESSIN LEVEL )

RECEIVED  
OCT 15 2002  
TECH CENTER 1600/2900

Commissioner for Patents  
Washington, DC 20231

Sir:

**SUPPLEMENTAL PRELIMINARY AMENDMENT**

Prior to the examination of the above application, please amend this application  
as follows:

**IN THE CLAIMS:**

Please amend claims 1-15, as follows:

1. (Twice Amended) A method of maintaining or increasing low vasopressin  
level comprising administering to a patient at least one substance that inhibits the  
binding between PTHrP and a receptor thereof, allowing the substance to inhibit the  
binding of PTHrP and its receptor, and maintaining or increasing vasopressin level.
2. (Twice Amended) The method according to claim 1, wherein the  
substance is an antagonist against a PTHrP receptor.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

10/10/2002 TBESHAM 00000086 10019501

01 FC:103  
02 FC:102

162.00 OP  
84.00 OP